{"title":"Forma Therapeutics与Celgene达成迄今为止最大的交易","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1936","DOIUrl":null,"url":null,"abstract":"Celgene has become Forma Therapeutics’ latest partner with a deal to discover, develop and commercialise drug candidates that regulate targets involved in protein homeostasis. Celgene will have the option to obtain the ex-US rights to multiple drug candidates after evaluating selected targets and lead assets in protein homeostasis pathways during the preclinical phase of the collaboration. In an evolution of deal structure for the company, Forma will be responsible for advancing compounds through the completion of Phase I in collaboration with its partner TGen Drug Development.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Forma Therapeutics Partners with Celgene in its Largest Deal to Date\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I5.1936\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Celgene has become Forma Therapeutics’ latest partner with a deal to discover, develop and commercialise drug candidates that regulate targets involved in protein homeostasis. Celgene will have the option to obtain the ex-US rights to multiple drug candidates after evaluating selected targets and lead assets in protein homeostasis pathways during the preclinical phase of the collaboration. In an evolution of deal structure for the company, Forma will be responsible for advancing compounds through the completion of Phase I in collaboration with its partner TGen Drug Development.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I5.1936\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I5.1936","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Forma Therapeutics Partners with Celgene in its Largest Deal to Date
Celgene has become Forma Therapeutics’ latest partner with a deal to discover, develop and commercialise drug candidates that regulate targets involved in protein homeostasis. Celgene will have the option to obtain the ex-US rights to multiple drug candidates after evaluating selected targets and lead assets in protein homeostasis pathways during the preclinical phase of the collaboration. In an evolution of deal structure for the company, Forma will be responsible for advancing compounds through the completion of Phase I in collaboration with its partner TGen Drug Development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
